TIDMPSY
RNS Number : 0500P
Psych Capital PLC
16 June 2022
Psych Capital Plc
("Psych Capital" or the "Company")
Awakn Reports Results for Quarter Ended April 30, 2022
Psych Capital Plc, the psychedelic healthcare incubation and
investment company, that operates the leading industry data,
insights, and networking platform PSYCH, announces that its
portfolio company Awakn Life Sciences ("Awakn") has announced
results and business highlights for the three months ended April
30, 2022.
1Q22 & Recent Business Highlights for Awakn:
-- Initiated follow-on behavioral study investigating Ketamine
as a treatment for Gambling Disorder
-- Filed Patent Cooperation Treaty (PCT) application for the
treatment of behavioral addictions with Ketamine and
Ketamine-assisted psychotherapy
-- Completed the world's first Ketamine study for a range of behavioral addictions
-- Announced successful completion of hit to lead drug discovery
program for new chemical entity (NCE)
-- Received regulatory approval for flagship clinic in London to begin delivering treatments
-- Filed patents for a new class of entactogen-like molecules
Anthony Tennyson, Chief Executive Officer of Awakn Life
Sciences, stated : "The results demonstrate the significant
momentum building in our business across both our research and
development pipeline and in our therapeutics commercialization
business. The addiction treatment market opportunity is,
unfortunately, large and growing, and Awakn is uniquely positioned
to offer proven therapeutics supported by data to sufferers for
whom the current standard of care is inadequate and relapse rates
are unacceptably high."
William Potts, Chief Investment Officer and Co-Founder of Psych
Capital, commented : "We are delighted with the progress Awakn has
made while maintaining a strong growth trajectory. We look forward
to further positive developments shortly as it continues to deliver
on its mission to revolutionise treatments for addiction."
The Company owns 426,000 common shares in Awakn, and at the
current price, values the Company's stake in Awakn at approximately
GBP213,000.
The full text of the announcement from Awakn can be found here:
Awakn Reports Results for Quarter Ended April 30, 2022
(awaknlifesciences.com)
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
Psych Capital Plc
Stephen Murphy, Executive
Director
William Potts, Chief Investment info@PSYCH.capital or via Walbrook
Officer PR Ltd psych@walbrookpr.com
AQSE Growth Market Corporate
Adviser
Peterhouse Capital Limited Tel: +44 (0) 207 469 0930
Guy Miller / Mark Anwyl
Walbrook PR Ltd (Media & Tel: +44 (0)20 7933 8780 or psych@walbrookpr.com
Investor Relations)
Nick Rome / Tom Cooper Mob: +44 (0) 7748 325 236 / +44
(0) 7971 221 972
About Psych Capital Plc
Psych Capital Plc identifies, funds and aims to support the
building of British and European companies across three core
pillars: therapeutic treatments, drug development, and data/AI. Its
mission is to support a new wave of innovators who are well
positioned to challenge the status-quo and revolutionise how
society deals with mental health conditions.
Through a network of analysts with deep industry knowledge and
capital markets expertise, Psych Capital is focussed on developing
a rigorously selected portfolio of industry leading companies at
the intersection of psychedelic medicine and technology.
The Psych Platform is a business-to-business media and content
platform for the psychedelic science and healthcare industry, and
it operates the website, https://psych.global/ . The Psych Platform
is a global B2B resource for networking, intelligence and insights,
servicing the industry through publications, newsletters and
engaging events. The Psych Platform has amassed a significant
global B2B audience, with over 20,000 subscribers to the
platform.
As a business-to-business media and content platform, the Psych
Platform also produces the PSYCH Symposium, a premium Live Event
series.
About Awakn
Awakn's Research & Development arm is engaged in
pre-clinical and clinical research to develop therapeutics to treat
addiction. It has drug discovery and clinical research programmes
active across substance and behavioural additions.
Its delivery arm deliver s these proven therapeutics through its
specialised clinics in the UK and Europe. The clinics will generate
real world data and evidence that supports our R&D activities.
It will establish licensing partnerships to deliver these
therapeutics globally, starting with the US and Canada in 2022.
Revenue generated from the clinics and licensing partnerships
will fund its ongoing research. Awakn is unique in the
biotechnology industry in that it has both a deep commercialisable
IP portfolio, and near-term scalable revenue streams.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXGPUQAQUPPGQA
(END) Dow Jones Newswires
June 16, 2022 02:00 ET (06:00 GMT)
Shortwave Life Sciences (AQSE:PSY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Shortwave Life Sciences (AQSE:PSY)
Historical Stock Chart
From Jan 2024 to Jan 2025
